Actuate Therapeutics’ (NASDAQ:ACTU) Lock-Up Period Set To Expire on February 10th

Actuate Therapeutics’ (NASDAQ:ACTU) lock-up period will expire on Monday, February 10th. Actuate Therapeutics had issued 2,800,000 shares in its initial public offering on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. After the end of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Actuate Therapeutics Stock Performance

NASDAQ:ACTU opened at $9.03 on Monday. Actuate Therapeutics has a 1 year low of $5.51 and a 1 year high of $11.73. The business has a 50 day moving average price of $8.46.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Actuate Therapeutics stock. KG&L Capital Management LLC acquired a new stake in shares of Actuate Therapeutics (NASDAQ:ACTU) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,000 shares of the company’s stock, valued at approximately $89,000. KG&L Capital Management LLC owned 0.06% of Actuate Therapeutics at the end of the most recent reporting period.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.